Meantime, the flurry of mergers and acquisition activity that began late last year and which launched the biotech sector into overdrive has slowed noticeably. Investors are still waiting to see whether hepatitis C developers Idenix Pharmaceuticals (IDIX) and Achillion Pharmaceuticals (ACHN) are taken out following similar deals for Pharmasset and Inhibitex.
9 Oil, Gold Stocks That Rise on Bad News
Where has all the good new in biotech gone?
--Written by Adam Feuerstein in Boston.
>To contact the writer of this article, click here: Adam Feuerstein.
>To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts